Please login
NASCOLA News - Bulletin Item
  

Posted: Monday, December 30, 2013

Stago Launches Products for Measurement of Apixaban

 

The STA® – Apixaban Calibrator and Controls are highly specific, automation-ready products for determining the apixaban concentration in plasma when used in conjunction with the STA® - Liquid Anti-Xa assay (catalog #s 00311US and 00322US).  This method has been shown to have excellent performance with respect to sensitivity, dynamic range of the assay, inter-subject variability and coefficient of variation (CV).1,2,3 

 

Apixaban (Eliquis®), a synthetically derived drug from Janssen Pharmaceuticals and Bayer Healthcare, inhibits the blood coagulation cascade by its inhibitory action on coagulation factor Xa, resulting in inhibition of fibrin clot formation.2

 

The STA® – Apixaban Calibrator (catalog # 01112) contains 4 calibrator points, establishing a linearity range of 20 to 500 ng/mL.  In addition, the STA® – Apixaban Control (catalog # 01111) product contains two levels of control at the low and high end of the calibrator range.  The calibrator is stable for 4 hours and the control for 8 hours on board the STA line of automated coagulation analyzers.  In addition, the reconstituted control is stable at 2-8° C for 7 days.

 

Utilization of STA® – Apixaban Calibrator and Controls ensures high specificity and precision for apixaban determination.  In addition, barcoding of critical information on the reagent vials prevents transcription errors.

 

The apixaban controls and calibrators are labeled for research use only, and are not for use in diagnostic procedures in the United States and Canada.

 

  1. Becker RC et al., Chromogenic laboratory assays to measure the factor-Xa inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32:  183-187
  2. Barret YC et al., Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104:  1263-1271
  3. Barret YC et al., A randomized assessment of the pharmacokinetic, pharmacodynamic, and safety intereaction between apixaband and enoxaparin in healthy subjects. Thromb Haemost 2012; 107:  916=924

About Diagnostica Stago, Inc.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.

 

ELIQUIS is a registered trademark of Bristol-Myers Squibb Company.

 

###

Contacts:

 

Hamid Erfanian, Director of Marketing

Diagnostica Stago, Inc.

(973) 867-2042

Hamid.Erfanian@us.stago.com